Use of vitamin D with anti-osteoporotic drugs: are available clinical trials telling us the whole story?

di Filippo, Luigi; Ulivieri, Fabio Massimo; Nuti, Ranuccio; Giustina, Andrea

doi:10.1007/s12020-023-03551-z

Cited by 6 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it was recently retrospectively observed that any type of bone-sparing therapy (either anti-resorptive with bisphosphonates and denosumab or anabolic with teriparatide) was able to lower the incidence of VFs only in biochemically active patients [ 107 ]. Nevertheless, despite the lack of specific evidence and guidelines on anti-osteoporotic treatment in acromegaly-related osteopathy, it has to be noted that if a bone-active treatment is felt to be indicated in a patient with acromegaly, a combination with cholecalciferol should be used, as in the general population [ 109 ].…”

Section: Treatment Of Acromegaly-related Osteopathymentioning

confidence: 99%

Acromegaly and Bone: An Update

Giustina

2023

Endocrinol Metab

View full text Add to dashboard Cite

Since our discovery in 2006 that acromegaly is associated with an increased risk of vertebral fractures, many authors have confirmed this finding in both cross-sectional and prospective studies. Due to the high epidemiological and clinical impact of this newly discovered comorbidity of acromegaly, this topic has progressively become more important and prominent over the years, and the pertinent literature has been enriched by new findings on the pathophysiology and treatment. The aim of this narrative review was to discuss these novel findings, integrating them with the seminal observations, in order to give the reader an updated view of how the field of acromegaly and bone is developing, from strong clinical observations to a mechanistic understanding and possible prevention and treatment.

show abstract

Section: Treatment Of Acromegaly-related Osteopathymentioning

confidence: 99%

Acromegaly and Bone: An Update

Giustina

2023

Endocrinol Metab

View full text Add to dashboard Cite

show abstract

Vitamin D in pituitary driven osteopathies

Chiloiro,

Costanza,

Riccardi

et al. 2024

Pituitary

View full text Add to dashboard Cite

The evidence that pituitary hormones may bypass peripheral endocrine glands to exert remarkable effects on the skeleton is gaining ground. Both hormonal excess and deficit may determine impairment in bone structure, and they commonly result in bone loss in patients affected by pituitary and neuroendocrine disorders. Vertebral fractures are the most common skeletal alterations and may occur independently of bone mass. Use of vitamin D (VD) supplementation is still debated in this setting. This review will focus on the interactions between different metabolites of VD and pituitary hormones, and the effects of VD supplementation on bone metabolism in patients with pituitary diseases.

show abstract

Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach

Giustina,

Giustina

2024

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Osteosarcopenia is an emerging clinical condition highly prevalent in the older people. Affected subjects due to their intrinsic skeletal fragility and propensity to falls are at elevated risk of hip fractures which can increase morbidity and mortality. Strategies for attenuating the impact of predisposing factors on hip fractures are not yet well defined and should derive from multidisciplinary care and collaborations. Our aim was to narratively review available data on the preventive role of vitamin D and hip protectors on hip fractures in older patients with sarcopenia. Older subjects are at high risk of vitamin D deficiency and of falls due to several concomitant factors besides osteosarcopenia. Vitamin D protective actions against hip fractures may be mediated by both skeletal (increased mineralization) and extra-skeletal (reduced risk of falls) actions. Hip protectors may act downstream attenuating the effects of falls although their use is still not yet enough widespread due to the suboptimal compliance obtained by traditional hard devices. Concomitant use of vitamin D and hip protectors may represent an effective strategy in the prevention of hip fractures which need to be tested in ad hoc designed clinical trials.

show abstract

Use of vitamin D with anti-osteoporotic drugs: are available clinical trials telling us the whole story?

Cited by 6 publications

References 50 publications

Acromegaly and Bone: An Update

Acromegaly and Bone: An Update

Vitamin D in pituitary driven osteopathies

Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach

Contact Info

Product

Resources

About